News
Curated oncology headlines from reputable sources, ranked by importance with Claude Opus 5.
News about: Invasive Breast Carcinoma → cancer profile · × Clear filters
AI model predicts which breast-cancer drugs work best
An AI model trained on millions of protein measurements can predict which drugs will be most effective in tissue samples from people with triple-negative breast cancer. It gauges drug effectiveness directly from proteomic profiling of biopsy material, in a subtype with historically limited targeted treatment options.
An operational perturbation proteomics-based virtual cell model
Researchers developed ProteinTalks, a virtual cell model built from temporal protein-abundance measurements in systematically perturbed breast cancer cell lines, enabling computational prediction across diverse drug discovery tasks. The model leverages large-scale perturbation proteomics to capture dynamic cellular responses and translate them into an operational tool for identifying drug targets …
Breast Cancer Drug Wins Approval Despite Rejection by Agency Advisors
The FDA granted accelerated approval to camizestrant (Etcamah) combined with a CDK4/6 inhibitor in adults with HR-positive, HER2-negative advanced breast cancer in whom an ESR1 mutation is detected in ctDNA during aromatase inhibitor plus CDK4/6 inhibitor therapy. The basis is the phase 3 SERENA-6 trial (n=315), where switching therapy on mutation detection extended progression-free survival from …
Scientists find breast cancer cells hiding behind protective “shields”
Researchers have mapped breast tumors at high resolution and identified hidden pockets of dormant cancer cells that may explain cancer recurrence after treatment. These quiescent cells can effectively hibernate, evading chemotherapy that targets rapidly dividing cells, and reactivate at a later time. The team discovered that dormant cells are frequently surrounded by immune cells and connective ti…
Alcohol-attributable cancer deaths in the USA doubled between 1990 and 2023
Cancer deaths attributable to alcohol in the USA rose from 11,361 in 1990 to 23,126 in 2023 — a doubling over 33 years. The figures come from a secondary analysis of Global Burden of Disease data, so they are attributable-fraction estimates rather than counted deaths: they describe the scale of the problem in a population, not the risk faced by any one person. Increases spanned liver, breast, colo…
MedPage Today roundup: FDA approves ropeginterferon alfa-2b for essential thrombocythemia — first new therapy for this myeloproliferative neoplasm since 1997
The FDA approved ropeginterferon alfa-2b (Besremi) for adults with essential thrombocythemia, marking the first new therapy for this chronic myeloproliferative neoplasm since anagrelide's approval in 1997. The roundup also highlights emerging data on AI-assisted mammography screening and a positive phase III trial result in multiple myeloma. Although Besremi was previously approved for polycythemi…
Phase 3 trial: neoadjuvant anbenitamab with albumin-bound docetaxel raised pathological complete response in HER2-positive breast cancer to 62.4%
In a phase 3 randomized trial in 521 patients with stage II-III HER2-positive breast cancer, neoadjuvant anbenitamab (a biparatopic HER2 antibody) with albumin-bound docetaxel achieved a total pathological complete response in 62.4% of patients (164/263) versus 51.2% (132/258) with standard trastuzumab, pertuzumab and docetaxel — an absolute difference of 11.4 percentage points (95% CI 3.2-19.6; P…
Psilocybin prevents chemotherapy-induced peripheral neuropathy in animal models through mitochondrial trafficking preservation
As few as two doses of psilocybin prevented chemotherapy-induced peripheral neuropathy (CIPN) in preclinical models by preserving mitochondrial trafficking in peripheral neurons, according to a study published in Science. CIPN is a disabling, often irreversible side effect that affects millions of cancer patients and frequently forces dose reductions or discontinuation of life-saving chemotherapy.…
Induced proximity comes of age
The May 2026 approval of vepdegestrant — restricted to ESR1-mutated, ER-positive, HER2-negative advanced breast cancer — made the first PROTAC degrader a clinical reality and validated induced proximity as a pharmacological modality: drugs that bring a target protein together with the cell's degradation machinery instead of merely blocking it. Nature Medicine argues the principle now reaches beyon…
Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial
In the randomized phase 3 NSABP B-59/GeparDouze trial, adding atezolizumab to neoadjuvant chemotherapy in early-stage triple-negative breast cancer did not improve event-free survival and the primary endpoint was not met. The pathological complete response rate was higher with atezolizumab (63.3% vs 57.0%), but the better tumour response to preoperative treatment did not translate into fewer recur…